Status:
COMPLETED
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Neurotoxicity
Unspecified Adult Solid Tumor, Protocol Specific
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Understanding how oxaliplatin affects hearing loss, dizziness, and peripheral neuropathy may improve the ability to plan effective treatment for patients receiving oxaliplatin for solid tum...
Detailed Description
OBJECTIVES: * Define the prevalence of audiometrically detectable hearing loss in patients with solid tumors treated with oxaliplatin. * Describe the association of chemotherapy-induced peripheral ne...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of solid tumor
- Received an oxaliplatin-containing chemotherapy regimen within the past 15 months\* NOTE: \*If oxaliplatin was omitted from the patient's most recent chemotherapy regimen due to ototoxicity, the patient is still eligible for participation in this study
- No known CNS metastases
- PATIENT CHARACTERISTICS:
- No history of spinal injuries
- ECOG performance status 0-3
- No history of chronic renal failure
- No known HIV/AIDS
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
November 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT00305799
Start Date
November 1 2005
End Date
November 1 2014
Last Update
November 24 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
2
MetroHealth Medical Center
Cleveland, Ohio, United States, 44109